Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors

NCT05584670 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05584670
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05584670 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 29, 2022
Completion date
June 28, 2028
Enrollment
542 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor